Medexus Pharmaceuticals (TSE:MDP) Upgraded at Raymond James

Medexus Pharmaceuticals (TSE:MDP) was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. The brokerage presently has a C$4.00 target price on the stock. Raymond James’ price target would indicate a potential downside of 1.72% from the stock’s previous close. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q3 2026 earnings at $0.22 EPS, Q4 2026 earnings at $0.23 EPS, FY2026 earnings at $0.89 EPS, FY2027 earnings at $0.88 EPS, FY2028 earnings at $0.80 EPS and FY2029 earnings at $0.77 EPS.

Several other equities analysts have also weighed in on MDP. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Leede Financial set a C$8.25 price objective on Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a report on Monday, September 30th. Two analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Strong Buy” and a consensus price target of C$5.25.

Medexus Pharmaceuticals Stock Performance

MDP stock opened at C$4.07 on Wednesday. Medexus Pharmaceuticals has a one year low of C$1.47 and a one year high of C$4.07. The firm’s fifty day moving average is C$2.74 and its 200 day moving average is C$2.52. The firm has a market cap of C$99.84 million, a PE ratio of 81.40 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.